Article
Medicine, General & Internal
Zhen Yu, Xiaojing Wei, Lanting Liu, Hao Sun, Teng Fang, Lu Wang, Ying Li, Weiwei Sui, Kefei Wang, Yi He, Yaozhong Zhao, Wenyang Huang, Gang An, Fancui Meng, Changjiang Huang, Tengteng Yu, Kenneth C. Anderson, Tao Cheng, Lugui Qiu, Mu Hao
Summary: The study suggests that Indirubin-3'-monoxime (I3MO), a derivative of Indirubin, exhibits anti-tumor activity in multiple myeloma (MM) by sensitizing MM cells to bortezomib-induced apoptosis. I3MO acts as a multifaceted regulator of cell death, inducing DNA damage, cell cycle arrest, and abrogating NF-KB activation. It down-regulates the expression of USP7, promotes NEK2 degradation, and suppresses NF-KB signaling. Moreover, I3MO directly binds to and down-regulates the proteasome activators PA28g (PSME3) and PA200 (PSME4). High expression of PSME3 and PSME4 is associated with poor outcome in relapsed/refractory MM (RRMM). Overall, I3MO represents a promising therapeutic strategy for MM.
Review
Biochemistry & Molecular Biology
Sri Murugan Poongkavithai Vadevoo, Smriti Gurung, Hyun-Su Lee, Gowri Rangaswamy Gunassekaran, Seok-Min Lee, Jae-Won Yoon, Yun-Ki Lee, Byungheon Lee
Summary: Peptides have lower affinity and a shorter half-life compared to antibodies, but they demonstrate higher efficiency in tissue penetration and cell internalization. Peptides have been used as tumor-homing ligands for delivering carriers and cargoes to tumors, and have also been conjugated with drugs to synthesize peptide-drug conjugates. Additionally, peptides selectively bind to cell surface receptors and proteins, and interfere with protein-protein interactions when internalized into cells. Therefore, peptides have great potential as multifunctional players in cancer therapy.
EXPERIMENTAL AND MOLECULAR MEDICINE
(2023)
Article
Multidisciplinary Sciences
Yuen Lam Dora Ng, Evelyn Ramberger, Stephan R. Bohl, Anna Dolnik, Christian Steinebach, Theresia Conrad, Sina Mueller, Oliver Popp, Miriam Kull, Mohamed Haji, Michael Guetschow, Hartmut Doehner, Wolfgang Walther, Ulrich Keller, Lars Bullinger, Philipp Mertins, Jan Kroenke
Summary: The study identifies CDK6 upregulation as a druggable target in IMiD-resistant multiple myeloma through integrated proteomic, phosphoproteomic, and RNA sequencing analysis.
NATURE COMMUNICATIONS
(2022)
Article
Biochemistry & Molecular Biology
Mingfei Zhang, Yanfei Zhu, Hongbin Yang, Xin Li, Rangwei Xu, Feng Zhu, Yunjiang Cheng
Summary: This study investigates the role of a citrus NOD26-like intrinsic protein, CsNIP5;1, in regulating water permeability. The results show that CsNIP5;1 reduces water loss in plant leaves and promotes seed germination under hyperosmotic stress. Overexpression of CsNIP5;1 also alleviates water loss in citrus fruit and callus during storage. The study further reveals that CsNIP5;1 may regulate water loss by influencing the accumulation of osmotic adjustment substances and the expression of other aquaporins. Additionally, CsWRKY4 and CsWRKY28 are identified as regulators of CsNIP5;1 during the postharvest period.
Article
Immunology
Mingyue Zhang, Jintong Chen, Hua Zhang, He Dong, Ying Yue, Siqing Wang
Summary: This study found that IL-10 enhances chemotherapy resistance in multiple myeloma through the FABP5 signaling pathway in macrophages. Targeting FABP5 may have important clinical implications.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Na He, Li Li, Rui Li, Si-Qi Zhang, Li-Hong Wu, Xian Guan, Qian-Yue Zhang, Tao Jiang, Jin-Bo Yang
Summary: In this study, several ageladine A derivative compounds were synthesized and compound 25 was found to be the most effective. Compound 25 showed inhibitory effects on STAT3 activation, reducing the expression of downstream genes and suppressing tumor cell proliferation and migration. In vivo experiments demonstrated that compound 25 effectively inhibited the growth of A549 tumors without significant weight loss.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Medicine, Research & Experimental
YingZheng Wang, Tong Wang, HuaXin Wang, WeiDong Liu, Xiao Li, XiaoYan Wang, YaNan Zhang
Summary: The antitumor effects of traditional drugs have received attention and active antitumor components extracted from traditional drugs have shown good efficacy. Cepharanthine (CEP) is an active component derived from Stephania plants that can inhibit tumor progression through multiple signaling pathways. By summarizing recent studies on CEP's antitumor effects and mechanism, this review aims to provide new insights and a theoretical basis for further development and application of CEP.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Engineering, Biomedical
Weijun Ji, Sidi Li, Xin Hou, Jin Zhao, Xubo Yuan
Summary: This paper reports a novel hemostatic material based on multiple non-covalent bond crosslinking, which exhibits excellent mechanical properties, good biocompatibility, storage stability, and rapid hemostasis ability. The material demonstrates effective hemostasis in experiments and maintains its mechanical properties and cell compatibility after storage.
ADVANCED HEALTHCARE MATERIALS
(2023)
Article
Biochemistry & Molecular Biology
Katia Grillone, Caterina Riillo, Roberta Rocca, Serena Ascrizzi, Virginia Spano, Francesca Scionti, Nicoletta Polera, Annalisa Maruca, Marilia Barreca, Giada Juli, Mariamena Arbitrio, Maria Teresa Di Martino, Daniele Caracciolo, Pierosandro Tagliaferri, Stefano Alcaro, Alessandra Montalbano, Paola Barraja, Pierfrancesco Tassone
Summary: A novel compound, SIX2G, was synthesized and found to inhibit cell viability, induce the expression of CD86 and CD69, and enhance the phagocytosis of tumor cells. These findings suggest the potential immunogenicity and anti-MM activity of SIX2G.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Nanoscience & Nanotechnology
Xi Luo, Sudan Wu, Meng Xiao, Huan Gu, Huan Zhang, Jianping Chen, Yang Liu, Chen Zhang, Jinming Zhang
Summary: Zein, derived from corn, is recognized as one of the safest biological materials by the US FDA. It has valuable characteristics that make it popular for preparing drug carriers to improve the therapeutic effect of antitumor drugs. However, the clinical translation of drug-loaded zein-based carriers is challenging due to insufficient research and strong hydrophobicity. This paper aims to introduce the interactions between loaded drugs and zein, administration routes, and the functionalization of zein-based drug delivery systems, demonstrating its potential and promoting further application.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2023)
Article
Veterinary Sciences
Vitoria Sequeira Goncalves, Francisco Denis Souza Santos, Alceu Goncalves dos Santos Junior, Renan Eugenio Araujo Piraine, Paulo Ricardo Centeno Rodrigues, Carolina Litchina Brasil, Neida Lucia Conrad, Fabio Pereira Leivas Leite
Summary: The study investigated the potential of recombinant IL17A to act as an adjuvant for a recombinant BoHV-5 glycoprotein D vaccine in cattle. The results showed that addition of rIL17 led to significantly higher levels of specific rgD-IgG and neutralizing antibodies compared to the control group. These findings suggest that rIL17A has adjuvant potential for vaccines against BoHV-5 and potentially other pathogens of cattle.
RESEARCH IN VETERINARY SCIENCE
(2021)
Article
Immunology
Madelon M. E. de Jong, Zoltan Kellermayer, Natalie Papazian, Sabrin Tahri, Davine Hofste Op Bruinink, Remco Hoogenboezem, Mathijs A. Sanders, Pieter C. van de Woestijne, P. Koen Bos, Cyrus Khandanpour, Jessica Vermeulen, Philippe Moreau, Mark van Duin, Annemiek Broijl, Pieter Sonneveld, Tom Cupedo
Summary: The progression and therapy response of multiple myeloma is influenced by the bone marrow niche. A study identified inflammatory mesenchymal stromal cells that interact with tumor cells, indicating a potential role in disease persistence. Tracking bone marrow inflammation over time revealed a link to disease persistence despite successful antitumor therapy.
Article
Chemistry, Physical
Nikolaos V. Tzouras, Leandros P. Zorba, Entzy Kaplanai, Nikolaos Tsoureas, David J. Nelson, Steven P. Nolan, Georgios C. Vougioukalakis
Summary: Despite the usefulness of gold catalysis in organic synthesis, it often requires activators and/or additives to generate cationic forms of gold catalysts. In this study, hexafluoroisopropanol (HFIP) is found to be a simple tool for gold-catalyzed cycloisomerizations, eliminating the need for external activators. HFIP acts as both a solvent and an activator through dynamic activation of the Au-Cl bond via hydrogen bonding. This unique mode of catalysis enables efficient and scalable cyclization reactions without the use of complex ligand/catalyst designs or activators.
Article
Hematology
Ilseyar Akhmetzyanova, Tonya Aaron, Phillip Galbo, Anastasia Tikhonova, Igor Dolgalev, Masato Tanaka, Iannis Aifantis, Deyou Zheng, Xingxing Zang, David Fooksman
Summary: The dissemination and progression of multiple myeloma is associated with an increased inflammatory signature in bone marrow MPs, with CD169(+) MPs playing a critical role in the early spread of myeloma.
Article
Hematology
Dan Chen, Teng Chen, Lihong Wang, Zhihua Zhang, Enhong Xing
Summary: In this study, it was found that the expression level of miR-448 in patients with MM was significantly higher than that in normal people and showed statistically differential expression in different stages of MM. Besides, miR-448 abundance in the plasma of newly diagnosed MM patients was positively correlated with the proportion of plasma cells in the bone marrow and the concentration of serum M protein. Additionally, ROC analysis demonstrated the sensitivity and specificity of miR-448 as a diagnostic marker for MM.
Review
Oncology
Federica Costa, Valentina Marchica, Paola Storti, Fabio Malavasi, Nicola Giuliani
Summary: Despite the debated use of PD-L1/PD-1 blockade in multiple myeloma (MM) patients, data on PD-1/PD-L1 expression profile and its potential link with CD38 pathways suggests a combined therapeutic approach could improve anti-tumoral effects in MM patients. Further studies are needed to clarify discrepancies in PD-1/PD-L1 distribution within the bone marrow microenvironment and to determine the efficacy of PD-1/PD-L1 blockade in reversing myeloma immune suppression and inhibiting myeloma cell survival.
Review
Cell Biology
Jessica Burroughs Garcia, Rosa Alba Eufemiese, Paola Storti, Gabriella Sammarelli, Luisa Craviotto, Giannalisa Todaro, Denise Toscani, Valentina Marchica, Nicola Giuliani
Summary: The amplification of 1q21 is a common cytogenetic abnormality in multiple myeloma, associated with poor response to standard therapies. The genes driving this amplification have not been fully studied, but potential candidates have been proposed as therapeutic targets. Understanding these genes is crucial for developing effective treatments for patients with 1q21 amplicon.
Article
Oncology
Stefano Baldoni, Beatrice Del Papa, Filomena De Falco, Erica Dorillo, Carlo Sorrentino, Chiara Rompietti, Francesco Maria Adamo, Manuel Nogarotto, Debora Cecchini, Elena Mondani, Estevao Carlos Silva Barcelos, Lorenzo Moretti, Maria Grazia Mameli, Bianca Fabi, Daniele Sorcini, Arianna Stella, Raffaella Giancola, Francesco Guardalupi, Francesca Ulbar, Sara Plebani, Valerio Guarente, Emanuela Rosati, Marta Di Nicola, Michele Marchioni, Mauro Di Ianni, Paolo Sportoletti
Summary: This study found that NOTCH1 activation is a negative prognostic factor in chronic lymphocytic leukemia (CLL) patients, significantly reducing Time To First Treatment (TTFT) regardless of NOTCH1 and IGHV mutation status. Activation of NOTCH2 and expression of JAGGED1 also influence clinical outcomes in this group, highlighting the need for further dedicated studies to refine CLL risk stratification using different components of the NOTCH network.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Stefania Livia Ciummo, Luigi D'Antonio, Carlo Sorrentino, Cristiano Fieni, Paola Lanuti, Giorgio Stassi, Matilde Todaro, Emma Di Carlo
Summary: CXCL1 acts as an autocrine growth factor for BCSCs, promoting tumor progression and immune escape. Targeting the CXCL1/CXCR2 axis could restrain the BCSC compartment and improve the treatment of aggressive BC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Immunology
Carlo Sorrentino, Luigi D'Antonio, Cristiano Fieni, Stefania Livia Ciummo, Emma Di Carlo
Summary: Colorectal cancer is a common cancer with a growing impact on public health. Immunotherapy shows promise in treatment, but resistance and limited patient eligibility are challenges. Understanding immune exhaustion in CRC is crucial for developing effective therapies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Carlo Sorrentino, Stefania Livia Ciummo, Luigi D'Antonio, Cristiano Fieni, Paola Lanuti, Alice Turdo, Matilde Todaro, Emma Di Carlo
Summary: IL30 plays a crucial role in regulating the viability and growth of breast cancer stem cells (BCSC) through juxtacrine signals and mediators such as CXCL10 and IL23. Targeting IL30 could potentially restrain the BCSC compartment and counteract breast cancer progression by disrupting its autocrine loops and immune subversion pathways.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Carlo Sorrentino, Luigi D'Antonio, Stefania Livia Ciummo, Cristiano Fieni, Lorena Landuzzi, Francesca Ruzzi, Simone Vespa, Paola Lanuti, Lavinia Vittoria Lotti, Pier Luigi Lollini, Emma Di Carlo
Summary: IL30 plays a crucial role in the development and progression of prostate cancer by regulating tumor driver genes and immunity-related genes. Targeting IL30 using CRISPR/Cas9-mediated therapy shows promise for clinical application.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Nicolas Thomas Iannozzi, Valentina Marchica, Denise Toscani, Jessica Burroughs Garcia, Nicola Giuliani, Paola Storti
Summary: Multiple myeloma is characterized by unregulated proliferations of plasma cells in bone marrow, which is influenced by the bone marrow microenvironment. The alterations of mesenchymal stromal cells and osteoblasts in multiple myeloma patients contribute to myeloma-associated bone disease. Understanding the characteristics and molecular pathways of these cells can provide insights into the pathophysiology of multiple myeloma.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Roberto Mina, Pellegrino Musto, Delia Rota-Scalabrini, Laura Paris, Barbara Gamberi, Angelo Palmas, Sara Aquino, Paolo de Fabritiis, Nicola Giuliani, Luca De Rosa, Alessandro Gozzetti, Claudia Cellini, Luca Bertamini, Andrea Capra, Daniela Oddolo, Iolanda Donatella Vincelli, Sonia Ronconi, Vincenzo Pavone, Norbert Pescosta, Michele Cea, Francesca Fioritoni, Stelvio Ballanti, Mariella Grasso, Elena Zamagni, Angelo Belotti, Mario Boccadoro, Francesca Gay
Summary: Maintenance treatment with carfilzomib plus lenalidomide for two years prolongs progression-free survival in patients with multiple myeloma. However, patients with two or more high-risk cytogenetic abnormalities still have an increased risk of progression and death.
Editorial Material
Hematology
Nicola Giuliani, Luisa Craviotto
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Oxana Lungu, Denise Toscani, Jessica Burroughs-Garcia, Nicola Giuliani
Summary: The study of osteoblast metabolism has attracted increasing attention recently due to its high energy demand during bone remodeling. In addition to glucose, recent data show that amino acid and fatty acid metabolism plays an important role in providing fuel for osteoblast functioning. Glutamine has been identified as a crucial amino acid for osteoblast differentiation and activity. This review focuses on the metabolic pathways involved in the fate and functions of osteoblasts, particularly in multiple myeloma (MM) bone disease where the presence of malignant plasma cells disrupts osteoblast formation and activity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Luigi D'Antonio, Cristiano Fieni, Stefania Livia Ciummo, Simone Vespa, Lavinia Lotti, Carlo Sorrentino, Emma Di Carlo
Summary: IL-30 is involved in the proliferation and migration of colorectal cancer stem cells and CRC cells, and its inactivation inhibits tumorigenicity and metastatic ability.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Carlo Sorrentino, Emma Di Carlo
Summary: Recent studies have emphasized the importance of molecular targeted therapies in metastatic castration-resistant prostate cancer. These therapies aim to block specific molecules and related pathways in cancer cells or their microenvironment to inhibit their growth and spread while minimizing harm to healthy tissues. The review discusses the characteristics, efficacy, and limitations of these therapies, some of which are already approved for clinical use, while others are still in clinical trials or pre-clinical development. It also explores future research perspectives, including combining traditional drugs and using nanomedicine for selective release at the tumor site, to improve tolerability and efficacy.
Article
Hematology
Cecilia Passeri, Ornella Iuliani, Mauro Di Ianni, Carlo Sorrentino, Raffaella Giancola, Luciano Abbruzzese, Franco M. Dallavalle, Salvatore Gattillo, Maria T. Mariano, Massimo Martino, Angelo Ostuni, Chiara Savignano, Luca Santoleri, Tiziana Tison, Michele Vacca, Patrizia Accorsi